Objective:The matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases that degrade all the components of the extracellular matrix (ECM). Several studies have demonstrated association between MMP gene polymorphisms and various cancers. The object of this study was to investigate whether the MMP-1 and MMP-9 gene promoter polymorphisms are associated with endometrial carcinomas in a Japanese population.
Methods:We compared the allele frequencies and genotype distributions of each single nucleotide polymorphism in the promoter regions of MMP-1 (- 1607 1G/2G) and MMP-9 (- 1562 C/T) in 107 endometrial carcinoma cases and 213 controls using polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) analysis.
Results:The allele frequencies of MMP-1 - 1607 2G and MMP-9 - 1562T were 64.0% and 10.7% in the cases and 70.0% and 16.7% in the controls, respectively. NO significant differences in the allele frequencies or genotype distributions were found between cases and controls for the MMP-1 - 1607 1G/2G polymorphism. However, a small but significant difference in the allele frequency of the MMP-9 - 1562T allele was noted between cases and controls (P = .046; odds ratio [OR] = 1.01; 95% confidence interval [CI], 1.01 to 2.73). Stratification by histology revealed a significant difference in the frequency of the MMP-9 - 1562T allele between endometrioid carcinoma cases (10.2%) and controls (P = .043; OR = 1.76; 95% CI, 1.02 to 3.03); we did not fihd a significant difference in the frequency of the MMP-9 - 1562T allele between non-endometrioid carcinoma cases (13.2%) and controls.
Conclusion:These results suggest that the MMP-9 - 1562 C/T polymorphism may be associated with susceptibility to endometrioid carcinoma in the Japanese population.
1. Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg75Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett2004;219:183-190.
2.
2. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer2000;7:227-242.
3.
3. Gu ZD, Chen KN, Li M, Gu J, Li JY. Cliical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol2005;11:871-874.
4.
4. Constance E, Brinckerhoff, Joni L, Ulrike B. Interstitial collagenases as markers of tumor progression. Clin Cancer Res2000;6:4823-4830.
5.
5. Xiaoping M, Chunyuan Y, Wen T, Ping X, Gang L, Wenfu L, Dongxin L. A functional polymorphism in the matrix metalloproteinase -2 gene promoter (- 1306 C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res2003;63:3987-3990.
6.
6. Sofia J, Carl W, Dirk H, Andreas M, Andreas H, Per E. Allelespecific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol2001;21:1834-1839.
7.
7. Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cncers and an insertion/deletion polymorphism in its promoter region. Cancer Res1999;59:4225-4227.
8.
8. Walter W, Dorothy R, Joni L, et al. Loss of heterozygosity on chromosome 11q22-23 in melanoma is asociated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol2001;158:691-697.
9.
9. Kroeger PE, Sarge KD, Morimoto RI. Mouse heat shock transcription factors 1 and 2 prefer a trimeric binding site but interact differently with the HSP70 heat shock element. Mol Cell Biol1993;13:3370-3383.
10.
10. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation1993;88:2180-2189.
11.
11. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet1997;350:1217-1219.
12.
12. Colby A, Charles I, Jennifer J, Constance E. Potential for the 2G single nucleotide polymorphisms in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res2002;62:7200-7202.
13.
13. Miyat Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res2003;9:1741-1749.
14.
14. Shu Y, Sahar D, Steven J, et al. Invasiveness of cutneous maligantn melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res2001;61:1296-1298.
15.
15. Giorgio G, Mari L, Jacopo M, et al. Matrix metalloproteinase 1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res2001;7:2344-2346.
16.
16. Yong Z, Margaret R, Lei L, Gordon B, Xifeng W. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res2001; 61:7825-7829.
17.
17. Stefan B, Hans J, Odette P, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation2003;107:1579-1585.
18.
18. David G, Amin K, Pamela L, Howard Y, RObert E. Functional polymorphism in the matrix metalloproteinase 9 promoter as a potential risk factor for intracranial aneurysm. Stroke1999;30:2612-2616.
19.
19. Pedro E, Samuel P, Mary S, et al. A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. Mol Hum Reprod2002;8:494-501.
20.
20. Itoh T, Tanioka M, Yoshida Y, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res1998;58:1048-1051.
21.
21. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell1998;92:391-400.
22.
22. Turpeenniemi-Hujnen T. Gelatinases and their natural inhibitors as prognostic indicators in solid cancers. Biochimie2005;87:287-297.
23.
23. Yimin W, Shumei F, Lizhen W, et al. No association between the C - 1562T polymorphism in the matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer2005;49:155-161.
24.
24. MOrgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinase as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res2004;33:44-50.
25.
25. Ouyang YW, Peng ZL, Yao XY, Liu SL, He YD. The expression of matrix metalloproteinase-2 and -9 in cervical cancer and a study of their relation. Sichuan Da Xue Xue Bao Yi Xue Ban2004;35:330-333.
26.
26. Aglund K, Rauvala M, Puistola U, et l. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol2004;94:699-704.
27.
27. Matsumura S, Oue S, Nakayama H, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol2005;131:19-25.
28.
28. Nishioka Y, Kobayashi K, Sagae S, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res2000;91:612-615.
29.
29. Santos MC, Campos MI, Souza AP, Trevilatto PC, Linc SR. Analysis of MMP-1 and MMp-9 promoter polymorphisms in early osseointegrated implant failure. Int J Oral Maxillofac Implants2004;19:38-43.
30.
30. Matsumura S, Oue N, Kitadai Y, et al. A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol2004;53:259-265.
31.
31. Yamad Y, Ando F, Niino N, Shimokata H. Association of a polymorphism of the matrix metalloproteinase-9 gene with bone mineral density in Japanese men. Metabolism2004;53:135-137.
32.
32. Zhang XM, Miao XP, Xiong P, et al. Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. Ai Zheng2004;23:1233-1237.
33.
33. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat2004;88:197-204.
34.
34. Lai HC, Chu CM, Lin YW, Chang CC, Nieh S, Yu MH, Chu TY. Matrix metalloproteinase-1 gene polymorphisms as a prognostic predictor of invasive cervical cancer. Gynecol Oncol2005;96:314-319.
35.
35. Giorgio G, Maria L, Marco D, Olivia T, Emma G, Roberto S. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphism are associated with carotid artery stenosis. Stroke2002;33:2408-2412.
36.
36. Ghilardi G, Biondi ML, Caputo M, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res2002;2:3820-3823.
37.
37. Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y. Association of functional polymorphisms of matrix metalloproteinase (MMP)-9 and MMP-3 genes with colorectal cancer. Int J Cancer. 2002;102:526-529.
38.
38. Jin X, Kuang G, Wei LZ, et al. No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol2005;11:2385-2389.
39.
39. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymph node metasis in breast cancer. J Exp Clin Cancer Res2004;23:121-125.
40.
40. Wenham RM, Calingaert B, Ali S, et al. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig2003;10:381-387.
